# Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

> **NCT02037529** · PHASE3 · SUSPENDED · sponsor: **Academic and Community Cancer Research United** · enrollment: 201 (actual)

## Conditions studied

- Breast Adenocarcinoma
- HER2/Neu Negative
- Invasive Breast Carcinoma
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Eribulin Mesylate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02037529
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2014-01-17
- **Primary completion:** 2021-02-11
- **Final completion:** 2024-10-31
- **Target enrollment:** 201 (ACTUAL)
- **Why stopped:** Total enrollment number is being lowered
- **Last updated:** 2024-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02037529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02037529, "Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02037529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*